Innovative screening models for the discovery of new schizophrenia drug therapies: an integrated approach

References

• Arguello PA, Markx S, Gogos JA, et al. Development of animal models for schizophrenia. Dis Model Mech. 2010 Jan-Feb;3(1–2):22–26.
   PubMed Web of Science ®Google Scholar
• Geyer MA, Olivier B, Joels M, et al. From antipsychotic to anti-schizophrenia drugs: role of animal models. Trends Pharmacol Sci. 2012 Oct;33(10):515–521.
   PubMed Web of Science ®Google Scholar
• Yang AC, Tsai SJ. New targets for schizophrenia treatment beyond the dopamine hypothesis. Int J Mol Sci. 2017 3;18(8):Aug.
   Web of Science ®Google Scholar
• Morris BJ, Pratt JA. Novel treatment strategies for schizophrenia from improved understanding of genetic risk. Clin Genet. 2014 Nov;86(5):401–411.
   PubMed Web of Science ®Google Scholar
• Liu S, Zhang F, Shugart YY, et al. The early growth response protein 1-miR-30a-5p-neurogenic differentiation factor 1 axis as a novel biomarker for schizophrenia diagnosis and treatment monitoring. Transl Psychiatry. 2017 Jan 10;7(1):e998.
   PubMedGoogle Scholar
• CMP O, Moran PM, Zhen XC, et al. Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies. Br J Pharmacol. 2017 Oct;174(19):3173–3190.
   PubMed Web of Science ®Google Scholar
• Taly A. Novel approaches to drug design for the treatment of schizophrenia. Expert Opin Drug Discov. 2013 Oct;8(10):1285–1296.
   PubMed Web of Science ®Google Scholar
• Lee YA, Goto Y. Reconsideration of animal models of schizophrenia and other psychiatric disorders with evolutionary perspective. Med Hypotheses. 2013 Dec;81(6):1120–1126.
   PubMed Web of Science ®Google Scholar
• Geyer MA, Markou A. Animal models of psychiatric disorders. Psychopharmacology: the fourth generation of progress. Lippincott, Williams & Wilkins. 1995. p. 787–798.
   Google Scholar
• Jones CA, Watson DJ, Fone KC. Animal models of schizophrenia. Br J Pharmacol. 2011 Oct;164(4):1162–1194.
   PubMed Web of Science ®Google Scholar
• van den Buuse M, Garner B, Gogos A, et al. Importance of animal models in schizophrenia research. Aust N Z J Psychiatry. 2005 Jul;39(7):550–557.
   PubMed Web of Science ®Google Scholar
• Marcotte ER, Pearson DM, Srivastava LK. Animal models of schizophrenia: a critical review. J Psychiatry Neurosci. 2001 Nov;26(5):395–410.
   PubMed Web of Science ®Google Scholar
• Geyer MA. Developing translational animal models for symptoms of schizophrenia or bipolar mania. Neurotox Res. 2008 Aug;14(1):71–78.
   PubMed Web of Science ®Google Scholar
• Becker A. Modeling schizophrenia: focus on developmental models. In Vivo Neuropharmacology and Neurophysiology. New York, NY: Humana Press. 2017. p. 369–388.
   Google Scholar
• Feifel D, Shilling PD. Promise and pitfalls of animal models of schizophrenia. Curr Psychiatry Rep. 2010 Aug;12(4):327–334.
   PubMed Web of Science ®Google Scholar
• Winship IR, Dursun SM, Baker GB, et al. An overview of animal models related to schizophrenia. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 2019 Jan;64(1):5–17.
   PubMed Web of Science ®Google Scholar
• Kesby JP, Eyles DW, McGrath JJ, et al. Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Transl Psychiatry. 2018 Jan 31;8(1):30.
   PubMed Web of Science ®Google Scholar
• van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull. 2010 Mar;36(2):246–270.
   PubMed Web of Science ®Google Scholar
• Ellenbroek B, Budde S, Cools A. Prepulse inhibition and latent inhibition: the role of dopamine in the medial prefrontal cortex. Neuroscience. 1996;75(2):535–542.
   PubMed Web of Science ®Google Scholar
• Pratt J, Winchester C, Dawson N, et al. Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nat Rev Drug Discov. 2012 Jun 22;11(7):560–579.
   PubMed Web of Science ®Google Scholar
• Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160(4):636–645.
   PubMed Web of Science ®Google Scholar
• Meyer F, Louilot A. Consequences at adulthood of transient inactivation of the parahippocampal and prefrontal regions during early development: new insights from a disconnection animal model for schizophrenia. Front Behav Neurosci. 2014;8:118.
   PubMed Web of Science ®Google Scholar
• Swerdlow NR, Braff DL, Hartston H, et al. Latent inhibition in schizophrenia. Schizophr Res. 1996 May;20(1–2):91–103.
   PubMed Web of Science ®Google Scholar
• Markou A, Chiamulera C, Geyer MA, et al. Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology. 2009 Jan;34(1):74–89.
   PubMed Web of Science ®Google Scholar
• Nuechterlein KH, Robbins TW, Einat H. Distinguishing separable domains of cognition in human and animal studies: what separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the measurement and treatment research to improve cognition in schizophrenia new approaches conference. Schizophr Bull. 2005 Oct; 31(4):870–874.
   PubMed Web of Science ®Google Scholar
• Marder SR. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin Neurosci. 2006;8(1):109–113.
   PubMedGoogle Scholar
• Millan MJ, Bales KL. Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: the CNTRICS initiative. Neurosci Biobehav Rev. 2013;37(9):2166–2180.
   PubMed Web of Science ®Google Scholar
• Klein MO, Battagello DS, Cardoso AR, et al. Dopamine: functions, signaling, and association with neurological diseases. Cell Mol Neurobiol. 2019 Jan;39(1):31–59.
   PubMed Web of Science ®Google Scholar
• Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009 Jan;66(1):13–20.
   PubMed Web of Science ®Google Scholar
• Jauhar S, Nour MM, Veronese M, et al. A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. JAMA Psychiatry. 2017 Dec 1;74(12):1206–1213.
   PubMed Web of Science ®Google Scholar
• Howes OD, McCutcheon R, Owen MJ, et al. The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry. 2017 Jan 1;81(1):9–20.
   PubMed Web of Science ®Google Scholar
• Grace AA, Gomes FV. The circuitry of dopamine system regulation and its disruption in schizophrenia: insights into treatment and prevention. Schizophr Bull. 2019 Jan 1;45(1):148–157.
   PubMed Web of Science ®Google Scholar
• Moore H. The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy. Schizophr Bull. 2010 Nov;36(6):1066–1072.
   PubMed Web of Science ®Google Scholar
• Sigurdsson T. Neural circuit dysfunction in schizophrenia: insights from animal models. Neuroscience. 2016 May;3(321):42–65.
   Google Scholar
• Yee BK, Singer P. A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia. Cell Tissue Res. 2013 Oct;354(1):221–246.
   PubMed Web of Science ®Google Scholar
• Tordjman S, Drapier D, Bonnot O, et al. Animal models relevant to schizophrenia and autism: validity and limitations. Behav Genet. 2007 Jan;37(1):61–78.
   PubMed Web of Science ®Google Scholar
• McCutcheon RA, Abi-Dargham A, Howes OD, et al. Dopamine and the striatum: from biology to symptoms. Trends Neurosci. 2019 Mar;42(3):205–220.
   PubMed Web of Science ®Google Scholar
• Bahner F, Meyer-Lindenberg A. Hippocampal-prefrontal connectivity as a translational phenotype for schizophrenia. Eur Neuropsychopharmacol. 2017 Feb;27(2):93–106.
   PubMed Web of Science ®Google Scholar
• P Jm M, AM. Current and future treatment modalities in schizophrenia: novel antipsychotic drugs and cognitive therapy. Expert Rev Neurother. 2014 Jan;14(1):67–73.
   PubMed Web of Science ®Google Scholar
• Nikiforuk A. Assessment of cognitive functions in animal models of schizophrenia. Pharmacol Rep. 2018 Aug;70(4):639–649.
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A. From “bedside” to “bench” and back: a translational approach to studying dopamine dysfunction in schizophrenia. Neuroscience & Biobehavioral Reviews. 2020 Mar 1;110:174–9
   Google Scholar
• Petty A, Cui X, Tesiram Y, et al. Enhanced Dopamine in Prodromal Schizophrenia (EDiPS): a new animal model of relevance to schizophrenia. NPJ schizophrenia. 2019 Mar 29;5(1):1.
   Google Scholar
• Howes OD, Montgomery AJ, Asselin M-C, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66(1):13–20.
   PubMed Web of Science ®Google Scholar
• Geyer MA, Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuro Psychopharmacol Biol Psychiatry. 2003;27(7):1071–1079.
   PubMed Web of Science ®Google Scholar
• Steeds H, Carhart-Harris RL, Stone JM. Drug models of schizophrenia. Ther Adv Psychopharmacol. 2015 Feb;5(1):43–58.
   PubMed Web of Science ®Google Scholar
• Dawson GR. Experimental medicine in psychiatry new approaches in schizophrenia, depression and cognition. Curr Top Behav Neurosci. 2016;28:475–497.
   PubMedGoogle Scholar
• Coyle JT. NMDA receptor and schizophrenia: a brief history. Schizophr Bull. 2012 Sep;38(5):920–926.
   PubMed Web of Science ®Google Scholar
• Pyndt Jorgensen B, Krych L, Pedersen TB, et al. Investigating the long-term effect of subchronic phencyclidine-treatment on novel object recognition and the association between the gut microbiota and behavior in the animal model of schizophrenia. Physiol Behav. 2015 Mar;15(141):32–39.
   Google Scholar
• Marona-Lewicka D, Nichols CD, Nichols DE. An animal model of schizophrenia based on chronic LSD administration: old idea, new results. Neuropharmacology. 2011 Sep;61(3):503–512.
   PubMed Web of Science ®Google Scholar
• Blackman RK, Macdonald AW 3rd, Chafee MV. Effects of ketamine on context-processing performance in monkeys: a new animal model of cognitive deficits in schizophrenia. Neuropsychopharmacology. 2013 Oct;38(11):2090–2100.
   PubMed Web of Science ®Google Scholar
• Halene TB, Ehrlichman RS, Liang Y, et al. Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia. Genes Brain Behav. 2009 Oct;8(7):661–675.
   PubMed Web of Science ®Google Scholar
• Adachi M. Toward understanding a mouse model of schizophrenia: from cellular and behavioral phenotypes to a biomarker of pathophysiology. Biol Psychiatry. 2018;83(9):S29.
   PubMed Web of Science ®Google Scholar
• Gill BJA, Khan FA, McKhann GM. You’re not hallucinating: potential new targets for schizophrenia treatment. Neurosurgery. 2019 Mar 1;84(3):E146–E147.
   PubMed Web of Science ®Google Scholar
• Cadinu D, Grayson B, Podda G, et al. NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology. 2018 Nov;142:41–62.
   PubMed Web of Science ®Google Scholar
• Passie T, Halpern JH, Stichtenoth DO, et al. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther Winter;. 2008;14(4):295–314.
   PubMed Web of Science ®Google Scholar
• Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008 Aug;165(8):1033–1039.
   PubMed Web of Science ®Google Scholar
• Singer P, Feldon J, Yee BK. Are DBA/2 mice associated with schizophrenia-like endophenotypes? a behavioural contrast with C57BL/6 mice. Psychopharmacology (Berl). 2009 Nov;206(4):677–698.
   PubMed Web of Science ®Google Scholar
• Tse MT, Piantadosi PT, Floresco SB. Prefrontal cortical gamma-aminobutyric acid transmission and cognitive function: drawing links to schizophrenia from preclinical research. Biol Psychiatry. 2015 Jun 1;77(11):929–939.
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Neill JC. Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine. J Psychopharmacol. 2016 Nov;30(11):1141–1144.
   PubMed Web of Science ®Google Scholar
• Carta MG, Paribello P, Preti A. How promising is neuroactive steroid drug discovery? Expert Opin Drug Discov. 2018 Nov;13(11):993–995.
   PubMed Web of Science ®Google Scholar
• Gupta S, Cahill JD, Ranganathan M, et al. The endocannabinoid system and schizophrenia: links to the underlying pathophysiology and to novel treatment approaches. J Clin Psychiatry. 2014 Mar;75(3):285–287.
   PubMed Web of Science ®Google Scholar
• Murray R, Englund A, Abi-Dargham A, et al. Cannabis-associated psychosis: neural substrate and clinical impact. Neuropharmacology. 2017;124:89–104.
   PubMed Web of Science ®Google Scholar
• Renard J, Rushlow WJ, Laviolette SR. What can rats tell us about adolescent cannabis exposure? insights from preclinical research. Can J Psychiatry. 2016;61(6):328–334.
   PubMed Web of Science ®Google Scholar
• Laviolette SR. Exploring the impact of adolescent exposure to cannabinoids and nicotine on psychiatric risk: insights from translational animal models. Psychological Medicine. Cambridge University Press. 2019. p. 1–8.
   Google Scholar
• Gill WD, Shelton HW, Burgess KC, et al. Effects of an adenosine A2A agonist on the rewarding associative properties of nicotine and neural plasticity in a rodent model of schizophrenia. J Psychopharmacol. 2020 Jan;34(1):137–144.
   PubMed Web of Science ®Google Scholar
• Rial D, Lara DR, Cunha RA. The adenosine neuromodulation system in schizophrenia. Int Rev Neurobiol. 2014;119:395–449.
   PubMed Web of Science ®Google Scholar
• Moscoso-Castro M, Gracia-Rubio I, Ciruela F, et al. Genetic blockade of adenosine A2A receptors induces cognitive impairments and anatomical changes related to psychotic symptoms in mice. Eur Neuropsychopharmacol. 2016 Jul;26(7):1227–1240.
   PubMed Web of Science ®Google Scholar
• Shen HY, Singer P, Lytle N, et al. Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. J Clin Invest. 2012 Jul;122(7):2567–2577.
   PubMed Web of Science ®Google Scholar
• Wei CJ, Singer P, Coelho J, et al. Selective inactivation of adenosine A(2A) receptors in striatal neurons enhances working memory and reversal learning. Learn Mem. 2011;18(7):459–474.
   PubMed Web of Science ®Google Scholar
• Kállai V, Tóth A, Gálosi R, et al. The MAM-E17 schizophrenia rat model: comprehensive behavioral analysis of pre-pubertal, pubertal and adult rats. Behav Brain Res. 2017;332:75–83.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Nakagawasai O, Sakuma W, et al. Prenatal treatment with methylazoxymethanol acetate as a neurodevelopmental disruption model of schizophrenia in mice. Neuropharmacology. 2019 May;15(150):1–14.
   Google Scholar
• Robertson GS, Hori SE, Powell KJ. Schizophrenia: an integrative approach to modelling a complex disorder. J Psychiatry Neurosci. 2006 May;31(3):157–167.
   PubMed Web of Science ®Google Scholar
• Idrizi R, Malcolm P, Weickert CS, et al. Striatal but not frontal cortical up-regulation of the epidermal growth factor receptor in rats exposed to immune activation in utero and cannabinoid treatment in adolescence. Psychiatry Res. 2016 Jun;30(240):260–264.
   Google Scholar
• Poulia N, Delis F, Brakatselos C, et al. Escalating low-dose delta(9) -tetrahydrocannabinol exposure during adolescence induces differential behavioral and neurochemical effects in male and female adult rats. Eur J Neurosci. 2020 Jul;52(1):2681–2693.
   PubMed Web of Science ®Google Scholar
• Zamberletti E, Beggiato S, Steardo L Jr., et al. Alterations of prefrontal cortex GABAergic transmission in the complex psychotic-like phenotype induced by adolescent delta-9-tetrahydrocannabinol exposure in rats. Neurobiol Dis. 2014 Mar;63:35–47.
   PubMed Web of Science ®Google Scholar
• van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature. 2010 Nov 11;468(7321):203–212.
   PubMed Web of Science ®Google Scholar
• Severance EG, Dickerson FB, Yolken RH. Autoimmune phenotypes in schizophrenia reveal novel treatment targets. Pharmacol Ther. 2018 Sep;189:184–198.
   PubMed Web of Science ®Google Scholar
• Cuomo A, Maina G, Rosso G, et al. The microbiome: a new target for research and treatment of schizophrenia and its resistant presentations? a systematic literature search and review. Front Pharmacol. 2018;9:1040.
   PubMed Web of Science ®Google Scholar
• Zhu F, Zhang L, Ding YQ, et al. Neonatal intrahippocampal injection of lipopolysaccharide induces deficits in social behavior and prepulse inhibition and microglial activation in rats: implication for a new schizophrenia animal model. Brain Behav Immun. 2014 May;38:166–174.
   PubMed Web of Science ®Google Scholar
• O’Leary C, Desbonnet L, Clarke N, et al. Phenotypic effects of maternal immune activation and early postnatal milieu in mice mutant for the schizophrenia risk gene neuregulin-1. Neuroscience. 2014;277:294–305.
   PubMed Web of Science ®Google Scholar
• Abazyan B, Nomura J, Kannan G, et al. Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol Psychiatry. 2010;68(12):1172–1181.
   PubMed Web of Science ®Google Scholar
• Schubert CR, Xi HS, Wendland JR, et al. Translating human genetics into novel treatment targets for schizophrenia. Neuron. 2014 Nov 5;84(3):537–541.
   PubMed Web of Science ®Google Scholar
• Ratajczak P, Kus K, Murawiecka P, et al. Biochemical and cognitive impairments observed in animal models of schizophrenia induced by prenatal stress paradigm or methylazoxymethanol acetate administration. Acta Neurobiol Exp (Wars). 2015;75(3):314–325.
   PubMed Web of Science ®Google Scholar
• Forsingdal A, Jorgensen TN, Olsen L, et al. Can animal models of copy number variants that predispose to schizophrenia elucidate underlying biology? Biol Psychiatry. 2019 Jan 1;85(1):13–24.
   PubMed Web of Science ®Google Scholar
• Hayashi-Takagi A. Synapse pathology and translational applications for schizophrenia. Neurosci Res. 2017 Jan;114:3–8.
   PubMed Web of Science ®Google Scholar
• Kanyuch N, Anderson S. Animal models of developmental neuropathology in schizophrenia. Schizophr Bull. 2017 Oct 21;43(6):1172–1175.
   PubMed Web of Science ®Google Scholar
• Falkai P, Hasan A, Rossner M, et al. Perspectives of neurobiological research in schizophrenia. Neurol Psychiatry Brain Res. 2016;22(2):63–68.
   Google Scholar
• Negron-Oyarzo I, Lara-Vasquez A, Palacios-Garcia I, et al. Schizophrenia and reelin: a model based on prenatal stress to study epigenetics, brain development and behavior. Biol Res. 2016 Mar;11(49):16.
   Google Scholar
• Kirik D, Howes O, Eyles D, et al. Genetic and animal model analyses reveal the pathogenic role of a novel deletion of RELN in schizophrenia. NPJ Schizophr. 2018 Aug 29;8(1):13046.
   Google Scholar
• Merenlender-Wagner A, Shemer Z, Touloumi O, et al. New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia. Autophagy. 2014;10(12):2324–2332.
   PubMed Web of Science ®Google Scholar
• Ayhan Y, McFarland R, Pletnikov MV. Animal models of gene-environment interaction in schizophrenia: A dimensional perspective. Prog Neurobiol. 2016 Jan;136:1–27.
   PubMed Web of Science ®Google Scholar
• Kokras N, Dalla C. Sex differences in animal models of psychiatric disorders. Br J Pharmacol. 2014;171(20):4595–4619.
   PubMed Web of Science ®Google Scholar
• Riecher-Rössler A, Butler S, Kulkarni J. Sex and gender differences in schizophrenic psychoses—a critical review. Arch Women’s Mental Health. 2018;21(6):627–648.
   PubMed Web of Science ®Google Scholar
• Wu YC, Hill RA, Gogos A, et al. Sex differences and the role of estrogen in animal models of schizophrenia: interaction with BDNF. Neuroscience. 2013 Jun;3(239):67–83.
   Google Scholar
• Gogos A, Ney LJ, Seymour N, et al. Sex differences in schizophrenia, bipolar disorder, and post‐traumatic stress disorder: are gonadal hormones the link? Br J Pharmacol. 2019;176(21): 4119–4135.
   Web of Science ®Google Scholar
• Barker-Collo S, Read J. The roles of gender and coping styles in the relationship between child abuse and the scl-90-r subscales’ psychoticism’and’paranoid ideation’. New Zealand J Psychol. 2011;40(3):30.
   Google Scholar
• Leger M, Neill JC. A systematic review comparing sex differences in cognitive function in schizophrenia and in rodent models for schizophrenia, implications for improved therapeutic strategies. Neurosci Biobehav Rev. 2016;68:979–1000.
   PubMed Web of Science ®Google Scholar
• Becker JB, Molenda H, Hummer DL. Gender differences in the behavioral responses to cocaine and amphetamine: implications for mechanisms mediating gender differences in drug abuse. Ann N Y Acad Sci. 2001;937(1):172–187.
   PubMedGoogle Scholar
• Snigdha S, Neill JC, McLean SL, et al. Phencyclidine (PCP)-induced disruption in cognitive performance is gender-specific and associated with a reduction in brain-derived neurotrophic factor (BDNF) in specific regions of the female rat brain. J Mol Neurosci. 2011;43(3):337–345.
   PubMed Web of Science ®Google Scholar
• Sutcliffe J, Rhaman F, Marshall K, et al. Oestradiol attenuates the cognitive deficit induced by acute phencyclidine treatment in mature female hooded-lister rats. J Psychopharmacol. 2008;22(8):918–922.
   PubMed Web of Science ®Google Scholar
• Javitt DC. Neurophysiological models for new treatment development in schizophrenia: early sensory approaches. Ann N Y Acad Sci. 2015 May;1344(1):92–104.
   PubMedGoogle Scholar
• Wong AH, Josselyn SA. Caution when diagnosing your mouse with schizophrenia: the use and misuse of model animals for understanding psychiatric disorders. Biol Psychiatry. 2016 Jan 1;79(1):32–38.
   PubMed Web of Science ®Google Scholar
• Moslem M, Olive J, Falk A Stem cell models of schizophrenia, what have we learned and what is the potential? Schizophrenia research. 2018 Dec 23.
   Google Scholar
• Jacobs BM. A dangerous method? the use of induced pluripotent stem cells as a model for schizophrenia. Schizophr Res. 2015 Oct;168(1–2):563–568.
   PubMed Web of Science ®Google Scholar
• Valton V, Romaniuk L, Douglas Steele J, et al. Comprehensive review: computational modelling of schizophrenia. Neurosci Biobehav Rev. 2017 Dec;83:631–646.
   PubMed Web of Science ®Google Scholar
• Diamantopoulou A, Gogos JA. Neurocognitive and perceptual processing in genetic mouse models of schizophrenia: emerging lessons. Neuroscientist. 2019 Jan;17:1073858418819435.
   Google Scholar
• Canetta S, Kellendonk C. Can we use mice to study schizophrenia? philosophical transactions of the royal society of london series B. Biol Sci. 2018 Mar 19;373(1742). 10.1098/rstb.2017.0032
   Google Scholar
• Matsumoto M, Walton NM, Yamada H, et al. The impact of genetics on future drug discovery in schizophrenia. Expert Opin Drug Discov. 2017 Jul;12(7):673–686.
   PubMed Web of Science ®Google Scholar
• Dunlop J, Brandon NJ. Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations? J Psychopharmacol. 2015 Feb;29(2):230–238.
   PubMed Web of Science ®Google Scholar
• Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology. 2000;23(3):223.
   PubMed Web of Science ®Google Scholar
• Phillips AG, Geyer MA, Robbins TW. Effective use of animal models for therapeutic development in psychiatric and substance use disorders. Biol Psychiatry. 2018;83(11):915–923.
   PubMed Web of Science ®Google Scholar
• Kokras N, Hodes GE, Bangasser A, et al. Sex differences in the HPA axis: an obstacle to antidepressant drug development? Br J Pharmacol. 2019;176(21):4090-4106.
   Google Scholar
• Insel TR, Voon V, Nye JS, et al. Innovative solutions to novel drug development in mental health. Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 1):2438–2444.
   PubMed Web of Science ®Google Scholar